Business Context and Reporting Period
This Form 8-K Current Report was filed by West Pharmaceutical Services, Inc. on April 22, 2025. The filing discloses significant changes in senior executive leadership, specifically the retirement of the Chief Financial Officer and the appointment of a new Senior Vice President for the Proprietary Segment.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Bernard Birkett, Senior Vice President and Chief Financial Officer, notified the company of his intention to retire later in 2025. He will remain in his current role until a successor is found and will transition to an advisory role until December 31, 2025.
- Appointment of New Executive: Shane Campbell was appointed as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025. He joins from Carlisle Companies Inc. and previously held senior roles at DuPont.
Compensation and Management Commentary
The filing details the employment agreement for Mr. Campbell, effective May 5, 2025:
- Base Salary: $600,000 annually.
- Annual Incentive: Target bonus of 75% of base salary, prorated for 2025.
- Long-Term Incentives (LTI): Initial award with a grant date fair value of $1,000,000 (50% PSUs, 25% stock options, 25% RSUs).
- Sign-on Awards: A one-time RSU award valued at $400,000 (vesting 25% annually through May 2029) and a cash sign-on bonus of $100,000.
- Clawback Provision: The $100,000 cash bonus is subject to a two-year repayment obligation if employment terminates prior to the second anniversary, except in cases of Constructive Termination, Death, Disability, or termination with Cause.
Investor Verification Checklist
- Verify the timeline for the CFO search and the specific date of Mr. Birkett's final day in his current role.
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed terms regarding change-in-control provisions and Executive Ownership Guidelines.
- Monitor future filings for the announcement of the new Chief Financial Officer.
- Assess the impact of the leadership transition on the Proprietary Products segment strategy.